Canopy Immuno-Therapeutics
Immunotherapeutic Approach for Autoimmunity and Life-threatening Allergies
Company Overview
Snapshot
Founded in December 2019 by Kfir Oved, Canopy Immuno-Therapeutics operates with 1–10 employees. The company has secured funding across two rounds. In December 2019, the company received its initial funding from TLV Partners.
Business overview
Canopy Immuno-Therapeutics is a preclinical-stage biotech company developing a new class of biologics. Its proprietary Reverse-Immunization platform aims to eliminate antigen-specific immunity, offering non-immunosuppressive treatments for autoimmune, allergic, and other antibody-mediated conditions. The company operates in the Health Tech & Life Sciences sector, focusing on drug discovery and development within pharmaceuticals and medical biotechnology.
Strategic signal
In November 2020, research co-authored by Canopy Immuno-Therapeutics' founder was published in The Lancet, detailing a multi-center nationwide comparison of seven SARS-CoV-2 serology assays. This publication highlights the company's scientific expertise and its contribution to understanding immune responses, signaling a strong foundation in immunology research relevant to its core mission of developing immunotherapeutic approaches.
Company Intelligence Q&A
- What is Canopy Immuno-Therapeutics' primary focus?
- Canopy Immuno-Therapeutics is focused on developing a new class of biologics using its proprietary Reverse-Immunization platform to provide non-immunosuppressive treatments for autoimmune, allergic, and other antibody-mediated conditions.
- When was Canopy Immuno-Therapeutics founded?
- Canopy Immuno-Therapeutics was founded in December 2019.
- Who are the founders of Canopy Immuno-Therapeutics?
- Kfir Oved is the founder and CEO of Canopy Immuno-Therapeutics.
- Which investor participated in Canopy Immuno-Therapeutics' funding round?
- In December 2019, TLV Partners participated in a funding round for Canopy Immuno-Therapeutics.
- What significant research has Canopy Immuno-Therapeutics been involved in?
- In November 2020, research co-authored by the company's founder was published in The Lancet, comparing seven SARS-CoV-2 serology assays and revealing a non-responding seronegative subpopulation.